yes rgs is a good comparison and it has started its run. with...

yes rgs is a good comparison and it has started its run. with cynata so tight now it should be easy in such a bullish biotech market to see the shares hit $1+ in a few weeks/months. they have IP which will see them able to partner with so many big pharma companies. The market really hasn't picked this up yet and the cyp reinstatement will be like a new ipo with potential for a spectacular debut. but i think it will come on and then the rise will build gradually. i am looking for over $2 by june 2014 based on the ip, the management's track record, the hot biotech market, and the new shareholders who are probably not in this for anything less than a 10/20x investment return.